Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man. NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10 mg DXR equivalent min(-1). The starting dose was 6 mg DXR equivalent m(-2), and the dose was escalated according to the accelerated titration method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4 neutropenia was observed at doses of 50 and 67 mg m(-2). Common nonhaematological toxicities were mild alopecia, stomatitis, and anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67 mg m(-2) (grade 4 neutropenia lasting more than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The C(5 min) and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23 patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be 50 mg m(-2) every 3 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This same concept was used by Kataoka and colleagues in a series of works leading to development of polymeric micelle NK911, which was evaluated clinically [146, 147].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).”
BackgroundSelf-citationWHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundAccelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639 · cited 2×
“Dose escalation was performed according to the previously described accelerated titration method (Simon et al, 1997).”
MethodDevelopment of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570 · cited 7×
“The hydrophobic inner core enables NK911 to entrap a sufficient amount of DXR. NK911 has a diameter of about 40 nm (Nakanishi et al, 2001).”
BackgroundMethodSelf-citationUziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477 · cited 1×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
Background(1991) · PubMed · Cited by 418
Cited by
Items 201–300 of 621
Ahn, D.-G., Lee, J., Park, S., Kwark, Y., & Lee, K. Y. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am505444c · Cited by 86
Multi-targeting cancer chemotherapy using temperature-responsive drug carrier systems
Nakayama, M., & Okano, T. (2010) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2010.08.006 · Cited by 86
Raveendran, R., Bhuvaneshwar, G. S., & Sharma, C. P. (2012) · Journal of Biomaterials Applications · doi:10.1177/0885328211427473 · Cited by 84
Nanomedicine for Treatment of Lung Cancer
Hussain, S. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_8 · Cited by 85
Clinical advances of nanocarrier-based cancer therapy and diagnostics
Luque-Michel, E., Imbuluzqueta, E., Sebastián, V., & Blanco‐Prieto, M. J. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1205585 · Cited by 91
Ultrasound-mediated micellar drug delivery
Rapoport, N. Y. (2012) · International Journal of Hyperthermia · doi:10.3109/02656736.2012.665567 · Cited by 89
Butt, A. M., Amin, M. C. I. M., Katas, H., Sarisuta, N., Witoonsaridsilp, W., & Benjakul, R. (2012) · Journal of Nanomaterials · doi:10.1155/2012/916573 · Cited by 82
Targeted Delivery System of Nanobiomaterials in Anticancer Therapy: From Cells to Clinics
Jin, S., Jin, H., & Hong, S. (2014) · BioMed Research International · doi:10.1155/2014/814208 · Cited by 95
Melnyk, T., Đorđević, S., Conejos‐Sánchez, I., & Vicent, M. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.007 · Cited by 87
Zhang, B., Wan, S., Peng, X., Zhao, M., Li, S., Pu, Y., & He, B. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00327a · Cited by 80
Disposition of Drugs in Block Copolymer Micelle Delivery Systems: From Discovery to Recovery
Aliabadi, H. M., Shahin, M., Brocks, D. R., & Lavasanifar, A. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847100-00001 · Cited by 84
Stimulus-Responsive Targeted Nanomicelles for Effective Cancer Therapy
Muthu, M. S., Rajesh, C. V., Mishra, A., & Singh, S. (2009) · Nanomedicine · doi:10.2217/nnm.09.44 · Cited by 81
Pearce, A. K., Simpson, J. D., Fletcher, N. L., Houston, Z. H., Fuchs, A. V., Russell, P. J., Whittaker, A. K., & Thurecht, K. J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.004 · Cited by 79
Specific Interactions Improve the Loading Capacity of Block Copolymer Micelles in Aqueous Media
Giacomelli, C., Schmidt, V., & Borsali, R. (2007) · Langmuir · doi:10.1021/la700337s · Cited by 77
Tian, Y., & Mao, S. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.681299 · Cited by 81
“Those formulations have already advanced to clinical trials for intravenous administration [10,11].”
BackgroundDrug nano-reservoirs synthesized using layer-by-layer technologies
Costa, R. R., Alatorre‐Meda, M., & Mano, J. F. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.04.005 · Cited by 85
Sun, H., Meng, F., Cheng, R., Deng, C., & Zhong, Z. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.783009 · Cited by 81
“It is interesting to note that several biodegradable micellar anticancer drugs (e.g., NK911 [6], NK105 [7], NK012 [8] and NC6004 [9]) have advanced to different phases of clinical trials [3,10].”
BackgroundGonçalves, M., Mignani, S., Rodrigues, J., & Tomás, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.016 · Cited by 75
Dehnoee, A., Kalbasi, R. J., Zangeneh, M. M., Delnavazi, M., & Zangeneh, A. (2022) · Micro & Nano Letters · doi:10.1049/mna2.12153 · Cited by 76
Wang, W., Sun, H., Meng, F., Ma, S., Liu, H., & Zhong, Z. (2012) · Soft Matter · doi:10.1039/c2sm07461c · Cited by 74
Bisphosphonate‐decorated lipid nanoparticles designed as drug carriers for bone diseases
Wang, G., Mostafa, N. Z., Incani, V., Kucharski, C., & Uludağ, H. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.34002 · Cited by 74
Polypeptides and polyaminoacids in drug delivery
González-Aramúndiz, J. V., Lozano, M. V., Sousa‐Herves, A., Fernández-Megía, E., & Csaba, N. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.647906 · Cited by 81
“This optimized PEG--PAsp (DOX) micelle has been studied in Phase I clinical trials as NK911 in Japan (Table 1) [40] and its structure is shown in Figure 2.”
MethodInfluentialvan (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s13482 · Cited by 79
Kaminskas, L. M., McLeod, V. M., Kelly, B. D., Cullinane, C. M., Sberna, G., Williamson, M., Boyd, B. J., Owen, D. J., & Porter, C. J. H. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200522d · Cited by 73
Novel SN-38–Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression
Sumitomo, M., Koizumi, F., Asano, T., Horiguchi, A., Ito, K., Asano, T., Kakizoe, T., Hayakawa, M., & Matsumura, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6532 · Cited by 72
Self-citationHira, S. K., Mishra, A. K., Ray, B., & Manna, P. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094309 · Cited by 71
“Several polymer based delivery systems like polymeric micelles [4], synthetic polymer conjugates”
BackgroundMultifunctional approaches utilizing polymeric micelles to circumvent multidrug resistant tumors
Kesharwani, S. S., Kaur, S., Tummala, H., & Sangamwar, A. T. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.10.022 · Cited by 78
Li, W., Nakayama, M., Akimoto, J., & Okano, T. (2011) · Polymer · doi:10.1016/j.polymer.2011.06.026 · Cited by 76
Rafi, M., Cabral, H., Kano, M. R., Mi, P., Iwata, C., Yashiro, M., Hirakawa, K., Miyazono, K., Nishiyama, N., & Kataoka, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.038 · Cited by 73
Sheihet, L., Piotrowska, K., Dubin, R. A., Kohn, J., & Devore, D. I. (2007) · Biomacromolecules · doi:10.1021/bm060860t · Cited by 74
Jiao, Y., Sun, Y., Tang, X., Ren, Q., & Yang, W. (2014) · Small · doi:10.1002/smll.201402297 · Cited by 69
Ke, W., Yin, W., Zha, Z., Mukerabigwi, J. F., Chen, W., Wang, Y., He, C., & Ge, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.006 · Cited by 69
Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy
Jeong, K., Kang, C. S., Kim, Y., Lee, Y.-D., Kwon, I. C., & Kim, S. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.050 · Cited by 72
Nanoparticle-Delivered Quercetin for Cancer Therapy
Men, K., Duan, X., Wei, X., Gou, M. L., Huang, M., Chen, L., Qian, Z. Y., & Yu, W. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520614666140521122932 · Cited by 72
Controlled Synthesis of Camptothecin−Polylactide Conjugates and Nanoconjugates
Tong, R., & Cheng, J. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900356g · Cited by 78
Supramolecular interaction in the action of drug delivery systems
Geng, W.-C., Jiang, Z.-T., Chen, S., & Guo, D. (2024) · Chemical Science · doi:10.1039/d3sc04585d · Cited by 77
“63,64 67 At ambient temperature, the majority of processes dominated by supramolecular interactions, such as hydrogen bonding, p stacking, and van der Waal interactions, are dynamic and reversible, owing to the signi cantly lower Gibbs energy barrier compared to chemical reactions.”
BackgroundLi, X., Li, P., Zhang, Y., Zhou, Y., Chen, X., Huang, Y., & Liu, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0147-1 · Cited by 68
Zhu, X., Yuan, J., Leung, K. C., Lee, S., Sham, K. W. Y., Cheng, C. H. K., Au, D. W. T., Teng, G., Ahuja, A. T., & Wáng, Y. X. J. (2012) · Nanoscale · doi:10.1039/c2nr30960b · Cited by 68
Chen, Y., Zhang, W., Gu, J., Ren, Q., Fan, Z., Zhong, W., Fang, X., & Sha, X. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.05.015 · Cited by 68
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114034 · Cited by 72
Pegylated Phospholipids-Based Self-Assembly with Water-Soluble Drugs
Wang, Y., Wang, R. L., Lu, X., Lü, W.-L., Zhang, C., & Liang, W. P. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-0029-6 · Cited by 69
A review on engineering polymer drug conjugates to improve combination chemotherapy
Vogus, D. R., Krishnan, V., & Mitragotri, S. (2017) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2017.08.002 · Cited by 68
Abourehab, M. A. S., Ahmed, O. A. A., Balata, G. F., & Almalki, W. H. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s168148 · Cited by 63
Intelligent thermoresponsive polymeric micelles for targeted drug delivery
Nakayama, M., & Okano, T. (2006) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(06)50005-x · Cited by 70
Akiyama, M., Ikeda, A., Shintani, T., Doi, Y., Kikuchi, J., Ogawa, T., Yogo, K., Takeya, T., & Yamamoto, N. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b719671g · Cited by 63
Sutton, D., Wang, S., Nasongkla, N., Gao, J., & Dormidontova, E. E. (2007) · Experimental Biology and Medicine · doi:10.3181/0702-rm-31 · Cited by 62
Dharmayanti, C., Gillam, T. A., Klingler‐Hoffmann, M., Albrecht, H., & Blencowe, A. (2021) · Polymers · doi:10.3390/polym13040624 · Cited by 68
“For instance, polymer-pep ide hybrid nanoparticles compose of PEG-b-poly(aspartic acid) and PEG-b-poly(glutam c acid) were utilised for he delivery of doxorubicin and a camptothecin de ivative (SN-38), respectively, and demonstrated promising clinical characteristics in Phase I tr als [30,31].”
MethodNanostructure-based drug delivery systems for brain targeting
Haque, S., Md, S., Alam, M. I., Sahni, J. K., Ali, J., & Baboota, S. (2011) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2011.608191 · Cited by 67
Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy
Ferreira, N. N., Ferreira, L. M. B., Miranda‐Gonçalves, V., Reis, R. M., Seraphim, T. V., Borges, J. C., Baltazar, F., & Gremião, M. P. D. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.06.028 · Cited by 62
Polymers for targeted and/or sustained drug delivery
Jagur‐Grodzinski, J. (2008) · Polymers for Advanced Technologies · doi:10.1002/pat.1304 · Cited by 68
Imlimthan, S., Correia, A., Figueiredo, P., Lintinen, K., Balasubramanian, V., Airaksinen, A. J., Kostiainen, M. A., Santos, H. A., & Sarparanta, M. P. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36856 · Cited by 66
Nanomedicine from amphiphilized prodrugs: Concept and clinical translation
Xiang, J., Liu, X., Yuan, G., Zhang, R., Zhou, Q., Xie, T., & Shen, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114027 · Cited by 65
Polymeric nanomedicines based on poly(lactide) and poly(lactide-co-glycolide)
Tong, R., Gabrielson, N. P., Fan, T. M., & Cheng, J. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2013.01.001 · Cited by 67
Jin, Q., Maji, S., & Agarwal, S. (2012) · Polymer Chemistry · doi:10.1039/c2py20364b · Cited by 58
Fang, X., Chen, Sha, X., Zhang, Zhong, Fan, Ren, & Chen (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s42368 · Cited by 58
Polymeric micelles for cancer therapy: 3 C’s to enhance efficacy
Talelli, M., Rijcken, C. J. F., Hennink, W. E., & Lammers, T. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.003 · Cited by 58
Li, Y., Lu, H., Liang, S., & Xu, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b03960 · Cited by 59
Polymeric nano-micelles: Versatile Platform for Targeted Delivery in Cancer
Mohamed, S. E.-S. H., Parayath, N. N., Taurin, S., & Greish, K. F. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.69 · Cited by 61
Block copolymer micelles as ocular drug delivery systems
Assiri, A. A., Glover, K., Mishra, D., Waite, D. T., Vora, L. K., & Thakur, R. R. S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104098 · Cited by 61
Koide, H., Asai, T., Kato, H., Ando, H., Shiraishi, K., Yokoyama, M., & Oku, N. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.049 · Cited by 64
“At present, a number of polymeric micelles encapsulating anticancer drugs are proceeding to clinical studies (Matsumura et al., 2004; Matsumura, 2008; Hamaguchi et al., 2007;).”
BackgroundYu, C., Zhou, Q., Xiao, F., Li, Y., Hu, H., Wan, Y., Li, Z., & Yang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b00048 · Cited by 56
Tong, R., Christian, D. A., Tang, L., Cabral, H., Baker, J. R., Kataoka, K., Discher, D. E., & Cheng, J. (2009) · MRS Bulletin · doi:10.1557/mrs2009.118 · Cited by 66
Nanoparticle Delivery Strategies to Target Doxorubicin to Tumor Cells and Reduce Side Effects
Wang, Y., Wei, X., Zhang, C., Zhang, F., & Liang, W. P. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.24 · Cited by 59
Shin, K., Klosterhoff, B. S., & Han, B. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00131 · Cited by 54
“24 hours.(27) For 1 and 3-hour treatments, after given drug exposure duration, the T-MOC was”
BackgroundPolymeric micelle nanoparticles for photodynamic treatment of head and neck cancer cells
Cohen, E. M., Ding, H., Kessinger, C. W., Khemtong, C., Gao, J., & Sumer, B. D. (2010) · Otolaryngology · doi:10.1016/j.otohns.2010.03.032 · Cited by 54
Ayen, W. Y., & Kumar, N. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0783-8 · Cited by 53
Effect of Iontophoresis on Topical Delivery of Doxorubicin-Loaded Solid Lipid Nanoparticles
Taveira, S. F., de Santana, D. C. A. S., Araújo, L. M. P. D. C., Marquele‐Oliveira, F., Nomizo, A., & Lopez, R. F. V. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.1834 · Cited by 56
Carbon nanomaterials in oncology: an expanding horizon
Mehra, N. K., Jain, A., & Nahar, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.013 · Cited by 51
Nanodrug Delivery Systems for the Treatment of Ovarian Cancer
Pantshwa, J. M., Kondiah, P. P. D., Choonara, Y. E., Marimuthu, T., & Pillay, V. (2020) · Cancers · doi:10.3390/cancers12010213 · Cited by 53
pH-responsive self-assembled nanoparticles for tumor-targeted drug delivery
Sun, H., Li, X., Liu, Q., Sheng, H., & Zhu, L. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2349124 · Cited by 55
“NK911 exhibited a prolonged blood circulation time than native DOX in a phase i clinical trial [250]. criPec ® Docetaxel (cPc634) is a pH-responsive SANPs loaded with docetaxel, which entered first-in-human research and completed phase i trials in 2018. cPc634 showed improved pharmacokinetics and…”
BackgroundClinical Nanomedicine: A Solution to the Chemotherapy Conundrum in Pediatric Leukemia Therapy
Krishnan, V., & Rajasekaran, A. K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.174 · Cited by 57
Hoang, B., Ekdawi, S. N., Reilly, R. M., & Allen, C. J. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400315p · Cited by 54
Bridging cancer biology and the patients' needs with nanotechnology-based approaches
Fonseca, N. A., Gregório, A. C., Valério-Fernandes, Â., Simões, S., & Moreira, J. N. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.002 · Cited by 58
The potential of polymeric micelles in the context of glioblastoma therapy
Morshed, R. A., Cheng, Y., Auffinger, B., Wegscheid, M. L., & Lesniak, M. S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00157 · Cited by 56
“In a phase I clinical study, NK911 was used to treat several other solid tumors including pancreatic, colorectal, esophageal, gall bladder, and stomach cancer as well as leiomyosarcoma (Matsumura et al., 2004).”
BackgroundA Brief Review on Advantages of Nano-based Drug Delivery Systems
Hami, Z. (2021) · Annals of Military and Health Sciences Research · doi:10.5812/amh.112274 · Cited by 68
“Examples of these nanomicelles are Genexol PM (33), NK911 (34), NK105 (35), NK012 (36), and NC6004 (37).”
Self-assembling polymer systems for advanced treatment of cancer and inflammation
Palao‐Suay, R., Gómez‐Mascaraque, L. G., Aguilar, M. R., Vázquez‐Lasa, B., & Román, J. S. (2015) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2015.07.005 · Cited by 54
Natural plant-derived anticancer drugs nanotherapeutics: a review on preclinical to clinical success
Varsha, K., Sharma, A., Kaur, A., Madan, J., Pandey, R. S., Jain, U. K., & Chandra, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46144-3.00028-3 · Cited by 59
Li, Q., Wu, X. L., & Jin, Y. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9797-7 · Cited by 47
Hu, J. Q., He, J., Cao, D., Zhang, M., & Ni, P. (2015) · Polymer Chemistry · doi:10.1039/c5py00023h · Cited by 48
Passive Targeting of Nanoparticles to Cancer
Patel, J. K., & Patel, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-06115-9_6 · Cited by 63
Ukawala, M., Rajyaguru, T., Chaudhari, K., Manjappa, A. S., Pimple, S. S., Babbar, A. K., Mathur, R., Mishra, A. K., & Murthy, R. S. R. (2012) · Drug Delivery · doi:10.3109/10717544.2012.657721 · Cited by 50
“These micelles have demonstrated their ability to efficiently solubilize lipophilic agents with altered drug pharmacokinetics and in several cases have been reached to clinical trials (Allen et al., 2000; Matsumura et al., 2004; Zhang et al., 2004; Forrest et al., 2008; Lee et al., 2008; Xiong et al., 2008) Micelles m…”
BackgroundTargeted Drug Delivery Systems for Pancreatic Cancer
Khare, V. R., Alam, N., Saneja, A., Dubey, R. D., & Gupta, P. N. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2036 · Cited by 48
Rapoport, N. Y., Gupta, R., Kim, Y.-S., & O’Neill, B. E. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.010 · Cited by 47
Biodegradable Stimuli-Responsive Polymeric Micelles for Treatment of Malignancy
Yan, L., & Li, X. D. (2016) · Current Pharmaceutical Biotechnology · doi:10.2174/138920101703160206142821 · Cited by 48
Synthesis of polyphosphazenes with different side groups and various tactics for drug delivery
Ullah, R. S., Wang, L., Yu, H., Abbasi, N. M., Akram, M. A., Ul-Abdin, Z., Saleem, M., Haroon, M., & Khan, R. U. (2017) · RSC Advances · doi:10.1039/c6ra27103k · Cited by 51
Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative
Alrushaid, S., Sayre, C. L., Yáñez, J. A., Forrest, M. L., Senadheera, S. N., Burczynski, F. J., Löbenberg, R., & Davies, N. M. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9030035 · Cited by 49
“Various additional drug delivery approaches have been undertaken to overcome the toxicity limitations of Dox, such as utilization of micelles [9], synthetic polymer conjugates [10], and antibody targeted carriers [11], with varied degrees of success.”
BackgroundNear-Infrared Light-Triggered Polymeric Nanomicelles for Cancer Therapy and Imaging
Li, L., Pang, X., & Liu, G. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00648 · Cited by 45
Saito, Y., Yasunaga, M., Kuroda, J., Koga, Y., & Matsumura, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00806.x · Cited by 45
Self-citationImmunomicelles for advancing personalized therapy
Sawant, R. R., Jhaveri, A. M., & Torchilin, V. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.003 · Cited by 49
Shen, Y., Li, Q., Tu, J., & Zhu, J. (2008) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2008.12.010 · Cited by 44
Nunziata, G., Borroni, A., & Rossi, F. (2025) · Chemical Engineering Journal Advances · doi:10.1016/j.ceja.2025.100759 · Cited by 49
Nanomicellar Carriers for Targeted Delivery of Anticancer Agents
Zhang, X., Huang, Y., & Li, S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.135 · Cited by 47
Recent Advances in Shell-Sheddable Nanoparticles for Cancer Therapy
Thambi, T., & Park, J. H. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.1977 · Cited by 43
“Genexol-PM PEG-PLA PTX Breast, lung cancer Approved [34] NK012 PEG-PGlu(SN-38) SN-38 Breast cancer Phase II [35] NK911 PEG-PAsp(DOX) DOX Various cancers Phase II [36] NK105 PEG-PAA PTX Breast cancer Phase III [37] NC6004 PEG-PGlu Cisplatin Various cancers Phase I [38]”
BackgroundKaneda, Y. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.510511 · Cited by 47
“Doxorubicin-encapsulating polymeric micelles provided from a venture company were studied in a Phase II clinical trial at the National Cancer Center Hospital in Japan [32].”
MethodInfluentialInterventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma
Li, J., Liu, F., Gupta, S. K., & Li, C. (2016) · Theranostics · doi:10.7150/thno.15122 · Cited by 44
“NK911 Polymeric micelles Doxorubicin II [72]”
Ahmad, Z., Lv, S., Tang, Z., Shah, A., & Chen, X. (2015) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2015.1107707 · Cited by 43
Synthesis and Self-Assembly of RGD-Functionalized PEO-PB Amphiphiles
Zupancich, J. A., Bates, F. S., & Hillmyer, M. A. (2009) · Biomacromolecules · doi:10.1021/bm900149b · Cited by 41
Mohanty, A. K., Dilnawaz, F., Mohanty, C., & Sahoo, S. K. (2010) · Drug Delivery · doi:10.3109/10717541003720688 · Cited by 43
“This is demonstrated in an early phase of clinical trials in Japan, Korea, and the US (Danson et al., 2004; Matsumura et al., 2004).”
BackgroundDevelopment of Electrochromic Devices
Pawlicka, A. (2009) · Recent Patents on Nanotechnology · doi:10.2174/187221009789177821 · Cited by 44
Fonge, H., Huang, H., Scollard, D. A., Reilly, R. M., & Allen, C. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.088 · Cited by 41
Metadata
- Authors
- Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., & Watanabe, N.
- Affiliations
- National Cancer Center Hospital East (JP)
- National Cancer Center Hospital (JP)
- Nippon Kayaku (Japan) (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2004-10-12
- Volume
- 91
- Issue
- 10
- Pages
- 1775-1781
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2410050
- OpenAlex
- W2056347214
- Cited by
- 623
- References
- 17
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 20 · 2023: 18 · 2022: 28 · 2021: 35 · 2020: 28 · 2019: 23 · 2018: 25 · 2017: 37 · 2016: 42 · 2015: 38 · 2014: 53 · 2013: 28 · 2012: 54
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- doxorubicin, polymeric micelles, supramolecular nanocarriers, maximum tolerated dose, dose-limiting toxicity, neutropenia, pharmacokinetics, solid tumors, metastatic pancreatic cancer, accelerated titration, recommended phase 2 dose, drug delivery
- MeSH terms
- Aged, Antineoplastic Agents, Doxorubicin, Drug Administration Schedule, Female, Humans, Male, Micelles, Middle Aged, Nausea, Neoplasms, Neutropenia, Peptides, Polyethylene Glycols, Vomiting, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.